Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 7.5% – Here’s Why

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) rose 7.5% during mid-day trading on Thursday . The stock traded as high as $0.26 and last traded at $0.25. Approximately 33,566,019 shares changed hands during trading, a decline of 48% from the average daily volume of 64,815,828 shares. The stock had previously closed at $0.23.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research report on Thursday, January 9th. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Trading Up 5.9 %

The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The business has a 50 day moving average price of $0.26 and a 200-day moving average price of $0.31. The company has a market cap of $45.97 million, a P/E ratio of 0.00 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.